| Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 256 | 2012 |
| miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ... Journal of cellular physiology 228 (7), 1506-1515, 2013 | 198 | 2013 |
| miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ... Cell death & disease 3 (11), e436-e436, 2012 | 187 | 2012 |
| miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies N Amodio, M Rossi, L Raimondi, MR Pitari, C Botta, P Tagliaferri, ... Oncotarget 6 (15), 12837, 2015 | 126 | 2015 |
| Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma N Amodio, MA Stamato, AM Gullà, E Morelli, E Romeo, L Raimondi, ... Molecular cancer therapeutics 15 (6), 1364-1375, 2016 | 120 | 2016 |
| Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ... Leukemia 29 (11), 2173-2183, 2015 | 120 | 2015 |
| A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells A Gulla, MT Di Martino, ME Gallo Cantafio, E Morelli, N Amodio, C Botta, ... Clinical cancer research 22 (5), 1222-1233, 2016 | 112 | 2016 |
| Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A Gullà, ... Oncotarget 6 (29), 27343, 2015 | 111 | 2015 |
| A p53‐dependent tumor suppressor network is induced by selective miR‐125a‐5p inhibition in multiple myeloma cells M Leotta, L Biamonte, L Raimondi, D Ronchetti, MT Di Martino, C Botta, ... Journal of cellular physiology 229 (12), 2106-2116, 2014 | 107 | 2014 |
| Protein kinase CK2 protects multiple myeloma cells from ER stress–induced apoptosis and from the cytotoxic effect of hsp90 inhibition through regulation of the unfolded protein … S Manni, A Brancalion, LQ Tubi, A Colpo, L Pavan, A Cabrelle, E Ave, ... Clinical cancer research 18 (7), 1888-1900, 2012 | 83 | 2012 |
| MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells C Botta, M Cuce, MR Pitari, D Caracciolo, A Gulla, E Morelli, C Riillo, ... Leukemia 32 (4), 1003-1015, 2018 | 60 | 2018 |
| Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 E Morelli, L Biamonte, C Federico, N Amodio, MT Di Martino, ... Blood, The Journal of the American Society of Hematology 132 (10), 1050-1063, 2018 | 59 | 2018 |
| miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. 2015; 6: 12837–61 N Amodio, M Rossi, L Raimondi, MR Pitari, C Botta, P Tagliaferri, ... | 4 | |
| Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential E Morelli, L Biamonte, C Federico, MT Di Martino, N Amodio, ... Cancer Research 76 (14_Supplement), 1077-1077, 2016 | | 2016 |
| Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo C Botta, M Rossi, MR Pitari, A Gullà, T Del Giudice, E Morelli, E Iuliano, ... Blood 122 (21), 4489, 2013 | | 2013 |
| Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related … MR Pitari, M Rossi, C Botta, E Morelli, A Gullà, E Iuliano, T Del Giudice, ... Blood 122 (21), 683, 2013 | | 2013 |
| miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells N Amodio, M Leotta, L Biamonte, T Calimeri, U Foresta, E Leone, ... 55th Annual Meeting of the Italian Cancer Society, 2013 | | 2013 |
| Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease M Rossi, MR Pitari, N Amodio, MT Di Martino, E Leone, F Conforti, ... Blood 120 (21), 3960, 2012 | | 2012 |
| MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Blood 118 (21), 2910, 2011 | | 2011 |
